Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.rubramed.com | |
Market Cap | 2.58 Cr. | |
Enterprise Value(EV) | 2.74 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 0.02 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | 286.78 | Trailing Twelve Months Ending 2022-12 |
Industry PE | 35.87 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 0.49 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 9.61 | Calculated using Price: 4.72 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 0.55 Cr. | 5,468,300 Shares |
FaceValue | 10 | |
Company Profile | ||
The main object of the company is to cater to wholesale and retail markets with distribution of medicines and other medical and surgical products. |
1 Day |
|
|
1 Week |
|
|
1 Month |
|
|
3 Month |
|
+4.89% |
6 Month |
|
+22.92% |
1 Year |
|
+60.0% |
2 Year |
|
+95.04% |
5 Year |
|
+52.26% |
10 Year |
|
+98.32% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | -1.68 | -159.53 | -1.76 | 8.48 | -48.73 | -4.59 | 12.20 | 2.02 | -13.95 | |
Return on Capital Employed (%) | -1.59 | -150.53 | -1.75 | 9.13 | -32.23 | -1.87 | 7.98 | 1.37 | -3.70 | |
Return on Assets (%) | -1.55 | -145.00 | -1.47 | 6.88 | -24.39 | -1.51 | 4.35 | 0.68 | -4.17 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 3 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |
Non Curr. Liab. | 0 | 0 | 0 | 0 | |||||||
Curr. Liab. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
Minority Int. | |||||||||||
Equity & Liab. | 4 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
Non Curr. Assets | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Curr. Assets | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 4 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 0 | 0 | 2 | 1 | 1 | 0 | 2 | 2 | |||
Other Income | 0 | ||||||||||
Total Income | 0 | 0 | 2 | 1 | 1 | 0 | 2 | 2 | |||
Total Expenditure | 0 | 0 | 0 | 0 | -2 | -1 | -1 | 0 | -2 | -2 | |
PBIDT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Interest | |||||||||||
Depreciation | |||||||||||
Taxation | 0 | 0 | 0 | ||||||||
Exceptional Items | -3 | 0 | 0 | 0 | |||||||
PAT | 0 | -3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Adjusted EPS | 0 | -6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | -1 | |
Cash Fr. Inv. | |||||||||||
Cash Fr. Finan. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
Net Change | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | -1 | ||
Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Thu, 30 Mar 2023
Closure of Trading Window Pursuant to the Companys Securities Dealing Code the Trading Window for dealing in the Companys Equity Shares will remain closed from Saturday April 1 2023 for all Designated Employees of the Company.The closure is in connection with the declaration of Audited financial results of the Company for the quarter and year ending March 31 2023. The Trading Window will open 48 hours after the said financial results are declared to the Stock Exchanges. |
Tue, 14 Feb 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication Submission of newspaper publication of Unaudited Financial Results for the quarter and Nine Month ended December 31 2022 |
Mon, 13 Feb 2023
Board Meeting Outcome for Outcome Of Board Meeting The Board of Directors of the Company at its meeting held on Monday February 13 2023 inter alia has considered and approved the Unaudited Standalone Financial Results along with Limited review report for the quarter ended December 31 2022 |
No Scans Found |